Wall Street analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to post sales of $5.74 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Theravance Biopharma’s earnings, with estimates ranging from $3.50 million to $9.12 million. Theravance Biopharma posted sales of $3.09 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 85.8%. The business is expected to report its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Theravance Biopharma will report full year sales of $5.74 million for the current financial year, with estimates ranging from $40.00 million to $67.90 million. For the next year, analysts expect that the firm will report sales of $90.20 million per share, with estimates ranging from $64.91 million to $105.70 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.49). The company had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $3.71 million. Theravance Biopharma had a negative net margin of 1,855.42% and a negative return on equity of 136.86%.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Woodford Investment Management Ltd increased its stake in Theravance Biopharma by 0.4% during the 4th quarter. Woodford Investment Management Ltd now owns 10,747,108 shares of the biopharmaceutical company’s stock worth $227,270,000 after buying an additional 41,000 shares during the period. Virtus Fund Advisers LLC purchased a new stake in Theravance Biopharma during the 4th quarter worth approximately $974,000. Teacher Retirement System of Texas purchased a new stake in Theravance Biopharma during the 4th quarter worth approximately $416,000. Schwab Charles Investment Management Inc. increased its stake in Theravance Biopharma by 4.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock worth $5,569,000 after buying an additional 8,119 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new stake in Theravance Biopharma during the 4th quarter worth approximately $313,000. 86.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Theravance Biopharma stock traded down $1.00 on Friday, reaching $23.23. The company had a trading volume of 153,463 shares, compared to its average volume of 268,237. The company has a market capitalization of $1,272.93, a price-to-earnings ratio of -4.26 and a beta of 1.81. Theravance Biopharma has a 52-week low of $22.90 and a 52-week high of $43.44. The company has a debt-to-equity ratio of 1.94, a quick ratio of 5.79 and a current ratio of 6.05.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3342044/5-74-million-in-sales-expected-for-theravance-biopharma-inc-tbph-this-quarter.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.